
Purple Biotech fell 79.0% from $8.01 to $1.68, behind the S&P 500's +11.0%. Its worst day was Jun 11 (−48.0%), and its low came Oct 27 at $0.94.
Nov 18, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Purple Biotech closed at its highest level of the year, 9.0% above where the year started.
+5.6%
EPS of $-19.85 missed the $-3.40 estimate on $0.00 revenue.
+6.8% · S&P 500 −0.6%
Story events cover the past 12 months · Times ET
Purple Biotech shares rose 21.1%, while the S&P 500 rose 1.2%.
+21.1%, the year's best day · S&P 500 +1.2%
EPS of $-0.09 beat the $-1.06 estimate on $0.00 revenue.
+6.5% · S&P 500 −1.2%
Purple Biotech shares fell 48.0%, while the S&P 500 rose 1.7%.
−48.0%, the year's worst day · S&P 500 +1.7%
EPS of $-0.41 beat the $-0.98 estimate on $0.00 revenue.
−0.7% · S&P 500 +0.6%
Purple Biotech shares rose 19.3%, while the S&P 500 rose 0.4%.
+19.3%, on 77M shares, the year's heaviest volume · S&P 500 +0.4%
Purple Biotech closed at its lowest level of the year, 88.3% below where the year started.
−7.0% · S&P 500 +0.6%
Where it ended: a close of $1.68 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 12, 2027 (EPS est. $-3.00).
Nothing in the past 12 months.
All PPBT dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PPBT and SPY from Benzinga historical bars. Not investment advice.